Categories: News

CORRECTION: Orion Corporation: Managers’ transactions – Liisa Hurme

ORION CORPORATION MANAGERS’ TRANSACTIONS 23 JULY 2021 at 15.30 EEST

Orion Oyj: Correction of the content of the Managers’s transaction notification

CORRECTION: Orion Corporation: Managers’ transactions – Liisa Hurme

Orion Corporation is correcting its stock exchange release from 23 July 2021 at 15.00 EEST. The present release is based on the amended Managers’ transactions notification received by the company. In the initial notification, the box “Legal person” was erroneously ticked. Additionally, the amended notification specifies the dates of the transactions.

The following are the contents of the amended Managerstransactions notification:

Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.

Orion Oyj – Managers’ Transactions
____________________________________________

Person subject to the notification requirement
Name: Aino Anna Liisa Hurme
Position: Other senior manager
Issuer: Orion Oyj
LEI: 74370029VAHCXDR7B745

Notification type: AMENDMENT
Reference number: 74370029VAHCXDR7B745_20210723122117_6
Amendment comment:
Amendment to the initial notification where “Legal person” was erroneously ticked. Also added another page for transaction carried out on 23 July 2021.
____________________________________________

Transaction date: 2021-07-22
Venue: NASDAQ HELSINKI LTD (XHEL)
Instrument type: SHARE
ISIN: FI0009014377
Nature of the transaction: DISPOSAL

Transaction details
(1): Volume: 1,000 Unit price: 35.01 EUR
(2): Volume: 1,000 Unit price: 35.008 EUR
(3): Volume: 5,000 Unit price: 35.1 EUR

Aggregated transactions
(3): Volume: 7,000 Volume weighted average price: 35.074 EUR
____________________________________________

Transaction date: 2021-07-23
Venue: NASDAQ HELSINKI LTD (XHEL)
Instrument type: SHARE
ISIN: FI0009014377
Nature of the transaction: DISPOSAL

Transaction details
(1): Volume: 5,700 Unit price: 35.3 EUR

Aggregated transactions
(1): Volume: 5,700 Volume weighted average price: 35.3 EUR

Orion Corporation

Timo Lappalainen

President and CEO

    Olli Huotari

SVP, Corporate Functions

 

                                                

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orion.fi/en
http://www.twitter.com/OrionCorpIR

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion’s pharmaceutical R&D are neurological disorders, oncology and respiratory diseases for which Orion develops inhaled pulmonary medication. Orion’s net sales in 2020 amounted to EUR 1,078 million and the company had about 3,300 employees at the end of the year. Orion’s A and B shares are listed on Nasdaq Helsinki.

Staff

Recent Posts

Standard Process Launches Cultivate, a New Practitioner Symposium Advancing Whole-Food Nutrition and Healthy Aging

Two immersive 2026 events in Seattle and Boston will offer up to 12 CE credits,…

7 minutes ago

Vericel Announces Preliminary 2025 Financial Results and Business Updates

Total Revenue Expected to be $276 Million  MACI Revenue Expected to be $239.5 Million Fourth…

7 minutes ago

Stroke Experts Challenge “90-Day Recovery” Myth: New Research Shows Patients Need Long-Term Care

Study published by Centre for Neuro Skills researchers in Brain Injury journal argues current insurance…

7 minutes ago

Femasys Announces Partnership with Refuah Health Center to Expand First-Line Access to FemaSeed® in Community-Based Care

Partnership enables broader adoption of FemaSeed through a trusted community health provider serving a large,…

7 minutes ago

IMDX Supports AST and ASHI STAR Working Group’s Call for Decentralized Transplant Monitoring

American Journal of Transplantation position paper also highlights value of absolute quantification of dd-cfDNA as…

7 minutes ago

Picard / SynCardia Featured on the Cruxx of MedTech Podcast

TUCSON, Ariz., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard”…

7 minutes ago